EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.
Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignant tumor with poor prognosis. Epidermal growth factor receptor (EGFR) is an important cell adhesion and signaling pathway mediator. The aim of this study was to evaluate the expression of EGFR in both pancreatic intraepithelial neoplasia (PanIN) and PDA and their relationship to clinicopathologic characteristics. Formalin-fixed, paraffin-embedded tissues including 81 cases with pancreatic ductal adenocarcinoma, 27 with normal pancreas, 16 with PanIN-1A, 18 with PanIN-1B, 11 with PanIN-2, and 24 with PanIN-3 were used for construction of tissue microarrays. Imunohistochemistry for EGFR was performed. Normal pancreatic ducts, PanIN-1A, and PanIN-1B did not show EGFR overexpression. EGFR overexpression was observed in 18.2% (2/9) of PanIN-2, 41.7% (10/14) of PanIN-3, and 64.2% (52/81) of PDA, respectively. Significantly higher EGFR overexpression was observed in PDAs than in PanIN lesions (P<0.05). No statistically significant correlation was observed between EGFR overexpression and patient age, sex, tumor location, size, histological grade, vascular invasion, lymph node metastasis and stage at presentation, respectively. In conclusion, EGFR expression increased from PanIN to PDA. EGFR may be involved in early stage in development of PDA.
Department of Pathology, Yeungnam University College of Medicine Daegu, Korea.
Seok Ju
SJ
Park
Department of Pathology, Yeungnam University College of Medicine Daegu, Korea.
Mi Jin
MJ
Gu
Department of Surgery, Yeungnam University College of Medicine Daegu, Korea.
Dong Shik
DS
Lee
Department of Surgery, Yeungnam University College of Medicine Daegu, Korea.
Sung Soo
SS
Yun
Department of Surgery, Yeungnam University College of Medicine Daegu, Korea.
Hong Jin
HJ
Kim
Department of Pathology, Yeungnam University College of Medicine Daegu, Korea.
Joon Hyuk
JH
Choi
D014408:Biomarkers, Tumor / Q000032:analysis*; D002278:Carcinoma in Situ / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D021441:Carcinoma, Pancreatic Ductal / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D013997:Time Factors; D046888:Tissue Array Analysis; D016896:Treatment Outcome; D015854:Up-Regulation
D014408:Biomarkers, Tumor; C512478:EGFR protein, human; D066246:ErbB Receptors
Epidermal growth factor receptor; pancreatic ductal adenocarcinoma; pancreatic intraepithelial neoplasia